CureVac Initiates Phase 2a Clinical Trial of COVID-19 Vaccine Candidate

Study conducted in Peru and Panama

30-Sep-2020 - CureVac N.V. announced that the first participant has been dosed in a Phase 2a clinical trial of its COVID-19 vaccine candidate, CVnCoV. The dose-confirmation study, entitled CV-NCOV-002, is being conducted in Peru and Panama and will enroll a total of 690 healthy participants in two distinct ...

Treatment of the first HIV positive patient in ABIVAX’s Phase IIa clinical trial with ABX464

03-Feb-2015 - ABIVAX announced that enrolment has been initiated and the first HIV positive patient dosed in a Phase IIa clinical trial of ABX464. ABX464 is a novel, small molecule inhibiting HIV replication through an entirely new mechanism. For the first time in the treatment of AIDS, this molecule could ...

Autifony Therapeutics announces initiation of Phase IIa study for first-in-class drug to treat tinnitus

24-Nov-2014 - Autifony Therapeutics Limited, which is pioneering the development of novel pharmaceutical treatments for hearing disorders, announced that it has initiated a Phase IIa study in tinnitus subjects with its lead compound AUT00063. This proof of concept study (called the QUIET-1 study, QUest In ...

NOXXON Initiates Phase IIa Study of Anti-Hepcidin Spiegelmer Lexaptepid Pegol (NOX-H94)

05-Aug-2014 - NOXXON Pharma announced the treatment of a first patient with its anti-hepcidin Spiegelmer® lexaptepid pegol (NOX-H94) in a phase IIa proof - of - concept clinical trial to treat erythropoietin (EPO) - hyporesponsive anemia in dialysis patients. This is the fourth clinical trial with lexaptepid ...

Initiation of a Phase IIa Clinical Study for Lynovex in Cystic Fibrosis

27-Jun-2014 - NovaBiotics Ltd, a Aberdeen-based speciality biotechnology company, announced the initiation of an open label/single arm Phase IIa clinical study to assess the safety, tolerability, pharmacokinetics and initial evidence of efficacy of orally-dosed Lynovex®. The Phase IIa trial will be undertaken ...

NOXXON Initiates Phase IIa of Anti-Hepcidin Spiegelmer NOX-H94

Anemia of Chronic Disease Study is Fourth Phase II Initiated by NOXXON in 2012

06-Dec-2012 - NOXXON Pharma announced the treatment of the first patients in a Phase IIa clinical trial of its anti-hepcidin Spiegelmer® NOX-H94 to treat anemia associated with chronic disease. This Phase IIa study was initiated following the successful completion of the clinical Phase I program, data from ...

InnaVirVax: Phase I/IIa clinical study of its VAC-3S immunotherapeutic vaccine for treatment of HIV infection achieved primary endpoint

05-Dec-2012 - InnaVirVax has just announced successful completion of the first clinical development phase for VAC-3S immunotherapy in the treatment of HIV infections.A phase I/IIa dose escalation study was performed in 24 patients living with HIV whose CD4 T-lymphocyte levels were higher than 200/mm3 and who ...

Acacia Pharma announces positive results from Phase IIa nausea & vomiting study

09-Oct-2012 - Acacia Pharma announced positive results from its Phase IIa proof-of-concept study investigating APD403 for the prevention of acute nausea & vomiting in cancer patients receiving the highly emetogenic chemotherapy drug cisplatin. Although a number of anti-emetics are available on the market, ...

NOXXON Initiates Phase IIa Trial of anti-CXCL12/SDF-1 Spiegelmer

NOX-A12 in Second Oncology Indication: Multiple Myeloma

28-Sep-2012 - NOXXON Pharma announced the treatment of the first cohort of three multiple myeloma (MM) patients in a Phase IIa clinical trial of its anti-CXCL12/SDF-1 (CXC chemokine ligand 12 / Stromal Cell-Derived Factor-1) Spiegelmer® NOX-A12. CXCL12 signaling has been shown to play an important role in the ...

Medivir: Phase IIa interferon free combination hepatitis C trial of Simeprevir (TMC435) and TMC647055

24-Sep-2012 - Medivir AB announced that simeprevir (TMC435) and TMC647055, a non-nucleoside inhibitor (NNI) will enter a phase IIa interferon free combination trial.Simeprevir is a once daily potent HCV NS3/4A protease inhibitor in phase III clinical development for the treatment of chronic hepatitis C jointly ...